Technical Articles

PD-L1 targeted antibodies, as the core force of tumor immunotherapy, restore the killing ability of T cells against tumors by blocking the immunosuppressive binding of PD-L1 and PD-1. Currently, it has become the standard treatment for 16 specific cancers and unlimited indications.